Second poster of the month for the kt-5000AI program, following the 31st Society for Neuro-Oncology Annual Meeting Second poster of the month for the kt-5000AI program, following the 31st Society for Neuro-Oncology Annual Meeting
-- First patient dosed with ATR 1072 in the Corventis™ Phase 1/2 clinical trial in PRKAG2 syndrome -- -- Nonclinical data showed ATR 1072 reversed cardiac glycogen accumulation and improved features of PRKAG2 syndrome -- -- Pro-forma cash balance at the end of September 2026 was $293.6 million with anticipated cash runway through 2028 -- SAN DIEGO, Nov. 12, 2026 /PRNewswire/ -- / PRNewswire/ – Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the third quarter ended September 30, 2026, and highlighted recent progress including dosing of the first patient in Corventis, its Phase 1/2 clinical trial of ATR 1072 in PRKAG2 syndrome, nonclinical data showing ATR 1072 reversed cardiac glycogen accumulation, and a $50 million private placement that extends its cash runway through 2028. "The last eight months have marked many firsts for Atrium, building toward our transition to a clinical stage company with the initiation of Corventis, the first clinical trial ever to target the root cause of PRKAG2 syndrome," said Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics.
NEW YORK, Nov. 10, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating AptarGroup, Inc. (NYSE: ATR) on behalf of the company's shareholders. The investigation seeks to determine whether AptarGroup's directors breached their fiduciary duties in connection with recent corporate actions.
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Poster to highlight AI-designed kt-5000AI compounds developed for PTEN-deficient brain tumours Poster to highlight AI-designed kt-5000AI compounds developed for PTEN-deficient brain tumours
I monitor dividend increases and cuts across 1,200+ stocks, focusing on dividend growth streaks, safety, and valuation to identify conviction opportunities. V, APH, and HIG stand out for robust dividend hikes, high-quality scores, and strong safety metrics. Energy names XOM and MPLX offer high yields and long growth streaks, but MPLX and SCL raise coverage and safety concerns because of their high payout ratios.
Examine AptarGroup's (ATR) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
-- ATR 1072 impacted key characteristics of PRKAG2 syndrome, including accumulation ofcardiac glycogen and cardiac hypertrophy -- -- Data further reinforce scientific rationale for ATR 1072 targeting the root cause ofPRKAG2 syndrome -- -- Poster presentation November 6 at 5:30 p.m. CT -- SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it will present new nonclinical data supporting its lead investigational therapy ATR 1072 for the potential treatment of PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome during Hypertrophic Cardiomyopathy Medical Society at the American Heart Association Scientific Sessions 2026, taking place on November 6, 2026, in Chicago, Illinois.
Beauty sales surged 8% but margins stumbled in North America, exposing an execution gap management must close.
Emerson is set to extend its dividend growth streak to 70 years, with a predicted 6.3–8.1% increase driven by a business transformation. EMR's shift to higher-margin Intelligent Devices and Software & Control segments supports a rebound in adjusted EPS, forecasted to grow 19% this year. Dividend growth across the broader group of long-term payers remains mostly mid-single digits, but several—including ADP, Assurant, and Atmos—are expected to announce 10%+ increases.